Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By

58 Results

  • Contains 8 Component(s) Includes Multiple Live Events. The next is on 08/03/2022 at 6:00 PM (EDT)

    This longitudinal, year-long program (June 2022-March 2023) will offer medical students (MS1-MS4) an opportunity to engage with experts in the field of addiction while working towards the completion of a research project. This opportunity offers interested medical students an opportunity to engage with the clinical and academic aspects of addiction treatment and research. This program will provide the tools to treat patients with Substance Use Disorders in whichever field or specialty you ultimately pursue.

    This longitudinal, year-long program (June 2022-March 2023) will offer medical students (MS1-MS4) an opportunity to engage with experts in the field of addiction while working towards the completion of a research project. 

    This opportunity offers interested medical students an opportunity to engage with the clinical and academic aspects of addiction treatment and research. This program will provide the tools to treat patients with Substance Use Disorders in whichever field or specialty you ultimately pursue.

    Schedule:

    Please watch "The Hungry Heart" prior to 6/1/22.  https://vimeo.com/ondemand/the...

    Dr. Kushner has asked that all mentees view the documentary film "The Hungry Heart" prior to her talk. It's about 90 minutes, and can be rented on Vimeo for $3.99. This should be the only time we ask mentees to spend any money on this program, but if you have issues/questions/concerns, please reach out to Dr. Latronica and we can find an arrangement. She also asked me to mention that some of the language in the documentary (specifically stigmatizing language) likely does not "hold up" in our current environment, but she believes the documentary as a whole is important viewing.

    Time Speaker Meeting 1: Introduction (6/1/22)
    6:00-8:00   Marla Kushner, D.O. "Addiction 101"
    Short Break      
    8:00-9:00   Whole Group Intro Session
         
    Time Speaker Meeting 2: Basics of Harm Reduction (8/3/22)
    6:00-7:00   Mentorship Breakout Groups
    Short Break    
    7:00-8:00 Elizabeth Salisbury-Afshar, M.D. Basics of Harm Reduction
    8:00-8:10   Whole Group Wrap-Up
         
    Time Speaker Meeting 3: Taking a Compassionate Substance Use History (9/7/22)
    6:00-7:00   Mentorship Breakout Groups
    Short Break    
    7:00-8:00 Veronica Ridpath, D.O. Taking a Compassionate Substance Use History
    8:00-8:10   Whole Group Wrap-Up
         
    Time Speaker Meeting 4: Opioid Use Disorder (10/5/22)
    6:00-7:00   Mentorship Breakout Groups
    Short Break    
    7:00-8:00  Katherine Grieco, D.O. Opioid Use Disorder
    8:00-8:10   Whole Group Wrap-Up
         
    Time Speaker Meeting 5: Alcohol Use Disorder (11/2/22)
    6:00-7:00   Mentorship Breakout Groups
    Short Break    
    7:00-8:00  Jon Lepley, D.O. Alcohol Use Disorder
    8:00-8:10   Whole Group Wrap-Up
         
    Time Speaker Meeting 6: Stimulant Use Disorder (12/7/22)
    6:00-7:00   Mentorship Breakout Groups
    Short Break    
    7:00-8:00  James Latronica, D.O. Stimulant Use Disorder
    8:00-8:10   Whole Group Wrap-Up
         
    Time Speaker Meeting 7:  Sedative/Hypnotic Use Disorder(2/1/23)
    6:00-7:00   Mentorship Breakout Groups
    Short Break    
    7:00-8:00  Steve Wyatt, D.O. Sedative/Hypnotic Use Disorder
    8:00-8:10   Whole Group Wrap-Up
         
    Time Speaker Meeting 8: Behavioral Addictions & Project Wrap-Up (3/1/23)
    6:00-7:00   Independent Project Presentations
    Short Break    
    7:00-8:00 Bhavna Bali, M.D. Behavioral Addictions/Malapdaptations
    8:00-8:10   Whole Group Wrap-Up

    Student Mentors:

    • William Bograkos, D.O.
    • Ralph Carbone, D.O.
    • Eric Hargis, D.O.
    • R. Gregory Lande, D.O.
    • David Leszkowitz, D.O.
    • Kristin Martin, D.O.
    • Michael Steelman, D.O.
    • Jan Widerman, D.O.
    • Andrew Williams, D.O.


  • Contains 4 Component(s), Includes Credits Includes a Live Web Event on 07/25/2022 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 5:00 pm Pacific Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.

    The presenter will be available to answer questions after the training has been completed.
    Please submit all questions to pcssmat@aoaam.org. All questions will be answered within 4-7 days.

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    William Morrone, DO, FAOAAM

    Medical Director at Recovery Pathways

    William Morrone, DO, MPH, DABAM, FACOFP & DAAPM, is Medical Director at Recovery Pathways, investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court, Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Dept of Psychiatry. He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management. Dr. Morrone is Director of the Saginaw Chippewa Tribal Court & commissioner on the Governor’s Impaired Driving Commission 2017-2019; he is also Assistant Prof Johns Hopkins School of Nursing.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • Contains 4 Component(s), Includes Credits Includes a Live Web Event on 07/09/2022 at 8:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 8:00 am Eastern Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.

    The presenter will be available to answer questions after the training has been completed.
    Please submit all questions to pcssmat@aoaam.org. All questions will be answered within 4-7 days.


    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • Contains 18 Component(s), Includes Credits Recorded On: 05/11/2022

    Opioid Response Network (ORN) - Hot Topics in Addiction Medicine - Spring 2022 Webinar Series

    Opioid Response Network (ORN) - Hot Topics in Addiction Medicine - Spring 2022 Webinar Series

    April 6, 2022, 2021 – 5 PM ET
         The Impact of Illicit Fentanyl Use on Opioid Use Disorder Treatment
         Andrew Huhn, PhD., M.B.A.

    April 13, 2022 – 5 PM ET
         Case Studies and Q&A: The Impact of Illicit Fentanyl Use on Opioid Use Disorder Treatment
         Andrew Huhn, PhD., M.B.A.

    April 20, 2022 – 5 PM ET
         Drugs, Stigma, and Health
         Robin A. Pollini, PhD MPH

    April 27, 2022 – 5 PM ET
         Case Studies and Q&A: Drugs, Stigma, and Health
         Robin A. Pollini, PhD MPH

    May 4, 2022 – 5 PM ET
         The Fourth Wave: Addressing the Intertwined Fentanyl and Stimulant Overdose Crisis 
         Daniel Ciccarone MD, MPH

    May 11, 2022 – 5 PM ET
         Case Studies and Q&A: The Fourth Wave: Addressing the Intertwined Fentanyl and Stimulant Overdose Crisis
         Steven Shoptaw, MD, PhD


    Andrew Huhn, PhD., M.B.A.

    My research is focused on understanding the human experience of opioid use and opioid use disorder (OUD). The majority of my work has been in human laboratory studies and clinical trials, and I have leveraged my background in psychology, neuroscience, and behavioral pharmacology to identify risk factors for illicit drug relapse and medication strategies to improve OUD treatment outcomes. These studies cover the continuum of care, including supervised opioid withdrawal and sustained recovery using medications for OUD. Topics of interest include sleep disturbance, drug craving, and diurnal measures of stress and mood. In addition, my work in OUD patients has naturally led me to investigate the tradeoffs between the abuse liability and analgesic efficacy of opioid medications, including research on persons with chronic and/or acute pain. My lab employs diverse methodological approaches to better understand opioid use and OUD, including neuroimaging, ecological momentary assessments, wearable technologies, human laboratory studies, and survey research. Taken together, this research is aimed at improving treatment outcomes directly and evaluating and strategizing macro-level changes to improve healthcare for substance use and related disorders.

    Robin Pollini, PhD, MPH

    Dr. Pollini is a substance use and infectious disease epidemiologist whose research focuses on mitigating the adverse health impacts of injection drug use; these include overdose, HIV, viral hepatitis, and serious injection-related bacterial infections like endocarditis. She uses innovative mixed methods study designs to examine how individual- and structural-level factors influence drug-related morbidity and mortality as well as health services access and utilization among people who inject drugs. Dr. Pollini has been Principal Investigator of several grants funded by the National Institute on Drug Abuse (NIDA).

    Daniel Ciccarone, MD, MPH

    Dr. Dan Ciccarone is the Justine Miner Professor in Addiction Medicine in the department of Family and Community Medicine at UCSF. He has been principal or co-investigator on numerous NIH sponsored public health research projects including his current Synthetics in Combination (SYNC) study. He is a recognized international scholar on the medical, public health and public policy dimensions of substance use, risks and consequences. He is Associate Editor for the International Journal of Drug Policy and recently edited an IJDP special issue on the ?triple wave crisis? of opioids, heroin and fentanyl in the US. He consults for numerous private and public entities including the ONDCP, CDC and FDA.

    Steven Shoptaw, PhD

    Steven Shoptaw PhD is Professor in UCLA Departments of Family Medicine and Psychiatry and Biobehavioral Sciences and Professor (Hon) in Psychiatry at the University of Cape Town. Dr. Shoptaw energetically leads research, clinical and policy efforts to bring novel and high impact strategies to deliver culturally competent care and prevention for persons affected by addictions and HIV. He leads two research centers at UCLA on addiction medicine and infectious diseases and is Protocol Co-Chair for an HIV Prevention Trials Network study evaluating a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care. Mentoring emerging clinical and research scholars from diverse backgrounds is a strong passion.

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM Past President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and Bridge Clinic, as well as the Narcotic Addiction Treatment Program.
    Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions. Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder. She is the Immediate Past President of the American Osteopathic Academy of Addiction Medicine.

  • Contains 3 Component(s), Includes Credits Recorded On: 02/10/2022

    Testimonies from the Trenches Series - Safer Pain Management Practices for Patients with Opioid Use Disorder. The presentation is planned to address how to manage painful conditions in patients on medications for opioid use disorder (MOUD).

    Testimonies from the Trenches: Innovations in Clinical Practice - 

    Safer Pain Management Practices for Patients with Opioid Use Disorder
    The presentation is planned to address how to manage painful conditions in patients on medications for opioid use disorder (MOUD).

    This webinar is free to AOAAM members.
    Non-members at $25. Consider membership!

    Learning objectives:

    1. Describe the neurobiology in the development of addiction
    2. Recognize unhealthy substance use patterns and distinguish between substance misuse and substance use disorder
    3. Analyze risk factors influencing pain management and the development of a substance use disorder
    4. Develop safer opioid prescribing for patients with opioid use disorder and to decrease risk for development of an opioid use disorder
    5. Understand how to use MOUD in treatment of painful conditions

    Outcomes:

    • This activity is designed to improve patient outcomes by increasing learner's knowledge of managing pain for patients on MOUD as well as decreasing the risk for the development of OUD.

    CME: This webinar series has been approved for a maximum 4, AOA Category 1-A CME credits, and AOA designates this for a maximum of 4, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

  • Contains 3 Component(s), Includes Credits Recorded On: 01/13/2022

    Testimonies from the Trenches: Buprenorphine in Residential Treatment Settings. This is a 30 minute didactic presentation. This presentation is a description of Buprenorphine as used in an inpatient residential treatment center. It will guide the practitioner through detox, inpatient care and the eventual discharge and post-discharge planning.

    Testimonies from the Trenches: Innovations in Clinical Practice - 

    Buprenorphine in Residential Treatment Settings. 
    This is a 30 minute didactic presentation with (.5 CME). This presentation is a description of Buprenorphine as used in an inpatient residential treatment center. It will guide the practitioner through detox, inpatient care and the eventual discharge and post-discharge planning.

    This webinar is free to AOAAM members.
    Non-members at $25. Consider membership!

    Learning objectives:

    1. Understand the Options of Medicated Assisted Treatment (MAT) for Opioid Use Disorders
    2. To create a framework for guiding a patient to the appropriate MAT
    3. Detox and Induction of Buprenorphine
    4. Post Discharge referrals

    Outcomes:

    • A comfort level on when and how to begin Buprenorphine in detox. (competence, performance)
      The process of making the best decision for an individual patient's MAT (competence, performance and patient outcomes)
      A look at the many factors that are involved in this process (competence)

    CME: This webinar series has been approved for a maximum 4, AOA Category 1-A CME credits, and AOA designates this for a maximum of 4, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Michael McCormick, DO

    Caron Foundation

    Michael A. McCormick, D.O., is the medical director of the Healthcare Professionals Program, a role he took on in January 2020, after serving as the addiction medicine provider for the program since its inception in 2016. He also leads Caron's Healthcare Professionals Assessment Program and provides daily care to the in-patient healthcare participants. As the physician in charge of the Opioid Treatment Program, he cares for patients who suffer from a particularly deadly disease, helping them with medication-assisted treatment decisions and induction of treatment.

    Employed by Richard J Caron Foundation

    Jon Lepley, DO (Moderator)

    AOAAM President Elect

    Jon Lepley, DO received his medical degree from Lake Erie College of Osteopathic Medicine and he completed his Family Medicine residency training at Heart of Lancaster Regional Medical Center. He is Board Certified by the American Osteopathic Board of Family Physicians, with a Certificate of Added Qualifications in Addiction Medicine. He is a Diplomate of the American Board of Addiction Medicine and he is recognized as a Certified Correctional Health Professional by the National Commission on Correctional Health Care. He has been conferred Fellow status by the American Society of Addiction Medicine.

    Dr. Lepley spent many formative years of practice providing healthcare within the Philadelphia Department of Prisons, wherein he pioneered a program which provides Medication Assisted Treatment to individuals suffering from opioid use disorder. His work in Philadelphia has been recognized by the College of Physicians of Philadelphia Section of Public Health and his program has been presented on a national level, garnering interest from large correctional systems across the country. Dr. Lepley’s clinical interests also include recognition of physician impairment and promotion of physician wellness. In this regard, he volunteers his time to serve on an Advisory Committee for the Pennsylvania Physician Health Program. His current professional role is with Penn Medicine as Medical Director of Addiction Medicine for the Lancaster General Health system.

     

  • Contains 3 Component(s), Includes Credits Recorded On: 12/09/2021

    Testimonies from the Trenches Series - Low-Barrier Buprenorphine Treatment. This is a short didactic presentation. This lecture will orient the audience to the tenants of low-barrier opioid use disorder treatment with buprenorphine. It will prepare learners to integrate this care into their practices.

    Testimonies from the Trenches: Innovations in Clinical Practice - 

    Low-Barrier Buprenorphine Treatment.
    This is a short didactic presentation. This lecture will orient the audience to the tenants of low-barrier opioid use disorder treatment with buprenorphine. It will prepare learners to integrate this care into their practices.

    This webinar is free to AOAAM members.
    Non-members at $25. Consider membership!

    Learning objectives:

    1. Introduce low-barrier buprenorphine treatment approaches
    2. Identify common barriers to receipt of OUD care with buprenporphine and review strategies to make care more accessible, including alternative induction approaches
    3. Increase comfort with providing OUD treatment to patients who have previously struggled to access care in traditional SUD treatment settings

    Outcomes:

    • This activity is designed to increase comfort and competence in offering low-barrier buprenorphine treatment and to treating patients who have struggled to engage in traditional OUD treatment programs. Participants will integrate low-barrier treatment approaches into their care and will be able to better serve patients with OUD.

    CME: This webinar series has been approved for a maximum 4, AOA Category 1-A CME credits, and AOA designates this for a maximum of 4, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Shoshana Aronowitz, PhD, MSHP, FNP-BC

    Shoshana Aronowitz is a family nurse practitioner, community-engaged health services researcher, and assistant professor in the Department of Family and Community Health at the University of Pennsylvania School of Nursing. Her research examines innovative delivery models to promote equitable access to substance use treatment and harm reduction services, as well as racial disparities in pain management in the context of the opioid overdose crisis. She received her bachelor?s degree from McGill University, her master?s in nursing from the University of Vermont, her PhD from the University of Pennsylvania School of Nursing, her master?s in health policy from the University of Pennsylvania School of Medicine, and completed her postdoctoral fellowship at the National Clinician Scholars Program University of Pennsylvania site. She provides substance use disorder treatment at Prevention Point Philadelphia and Ophelia Health. In addition, she is a member of SOL Collective, a grassroots harm reduction organization located in Philadelphia.

  • Contains 3 Component(s), Includes Credits Recorded On: 11/11/2021

    Testimonies from the Trenches Series - Reconsidering the Role of Urine Drug Testing in OUD Treatment. This is a 15 minute didactic presentation. Experiences providing care during the COVID-19 pandemic has forced us to use measures other than Urine Drug Testing (UDT) to define successful treatment. The role of UDT warrants re-examination as we emerge from the pandemic.

    Testimonies from the Trenches: Innovations in Clinical Practice - 

    Reconsidering the Role of Urine Drug Testing in OUD Treatment
    This is a 15 minute didactic presentation. Experiences providing care during the COVID-19 pandemic has forced us to use measures other than Urine Drug Testing (UDT) to define successful treatment. The role of UDT warrants re-examination as we emerge from the pandemic. (This webinar is available for .25 CME)

    This webinar is free to AOAAM members.
    Non-members at $25. Consider membership!

    Learning objectives:

    1. Discuss the patient-centered harms and benefits of routine urine drug testing
    2. Review on a high-level the literature on the practice of urine drug testing in addiction treatment
    3. Consider alternative approaches to routine urine drug testing

    Outcomes:

    • The activity is designed to encourage clinicians to consider modifying their clinical practice to improve the patient experience.

    CME: This webinar series has been approved for a maximum 4, AOA Category 1-A CME credits, and AOA designates this for a maximum of 4, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Utsha Khatri, MD, MSHP

    Utsha G. Khatri, MD MSHP is an Assistant Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai. She has a secondary appointment at the Institute for Health Equity Research, Department of Population Health Science and Policy. As a health services researcher, Dr. Khatri is interested in improving access, outcomes, and equity with regards to the health and health care of structurally marginalized populations. Her ongoing projects focus on the health care of individuals and communities affected by mass incarceration and those affected by substance use disorders. Dr. Khatri practices clinically as an attending emergency physician at Mount Sinai Hospital and at Elmhurst Hospital in New York City. Dr. Khatri received her medical degree from the George Washington School of Medicine and Health Sciences. She trained in Emergency Medicine at the University of Pennsylvania, where she served as chief resident. She completed the National Clinical Scholars Program at the University of Pennsylvania and received a Master?s degree in Health Policy Research.

    Employed by Mount Sinai Hospital

    Jon Lepley, DO (Moderator)

    AOAAM President Elect

    Jon Lepley, DO received his medical degree from Lake Erie College of Osteopathic Medicine and he completed his Family Medicine residency training at Heart of Lancaster Regional Medical Center. He is Board Certified by the American Osteopathic Board of Family Physicians, with a Certificate of Added Qualifications in Addiction Medicine. He is a Diplomate of the American Board of Addiction Medicine and he is recognized as a Certified Correctional Health Professional by the National Commission on Correctional Health Care. He has been conferred Fellow status by the American Society of Addiction Medicine.

    Dr. Lepley spent many formative years of practice providing healthcare within the Philadelphia Department of Prisons, wherein he pioneered a program which provides Medication Assisted Treatment to individuals suffering from opioid use disorder. His work in Philadelphia has been recognized by the College of Physicians of Philadelphia Section of Public Health and his program has been presented on a national level, garnering interest from large correctional systems across the country. Dr. Lepley’s clinical interests also include recognition of physician impairment and promotion of physician wellness. In this regard, he volunteers his time to serve on an Advisory Committee for the Pennsylvania Physician Health Program. His current professional role is with Penn Medicine as Medical Director of Addiction Medicine for the Lancaster General Health system.

     

  • Contains 3 Component(s), Includes Credits Recorded On: 09/22/2021

    (Part 2) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic. If you have not registered for one of our webinars in the past, please subscribe to AOAAM (https://aoaam.org/subscribe), then login and register for the webinars. This webinar has been approved for a maximum 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    (Part 2) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic.

    If you have not registered for one of our webinars in the past, please subscribe to AOAAM, then login and register for the webinars.

    Goals & Objectives: 

    1. TBA

    Needs Assessment: 

    TBA

    This webinar series has been approved for a maximum 6, AOA Category 1-A CME credits, and AOA designates this for a maximum of 6, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Davida Schiff, MD

    MassGeneral for Children

    Dr. Schiff is a general academic pediatrician and health services researcher focused on understanding how substance use in pregnant and parenting women impacts the health of children and families. She is the Medical Director of the HOPE Clinic (Harnessing support for Opioid and substance use disorder in Pregnancy and Early childhood) at Massachusetts General Hospital, a multidisciplinary program caring for women and families with substance use disorder from the time of conception through the first two years postpartum.

    Dr. Schiff completed her undergraduate training at Columbia University, medical training at the Boston University School of Medicine, pediatrics residency in the Boston Combined Residency Program at Boston Medical Center and Boston Children’s Hospital, general pediatrics research fellowship at Boston Medical Center, and master’s program in health services research from the Boston University School of Public Health. Her research is focused on improving care for families affected by substance use and her past scholarship has been published in the New England Journal of Medicine, JAMA, Pediatrics, Academic Pediatrics, Journal of Substance Abuse and Treatment, and Substance Abuse, among other journals. She is an Assistant Professor of pediatrics at Harvard Medical School.

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM Past President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and Bridge Clinic, as well as the Narcotic Addiction Treatment Program.
    Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions. Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder. She is the Immediate Past President of the American Osteopathic Academy of Addiction Medicine.

  • Contains 3 Component(s), Includes Credits Recorded On: 09/15/2021

    (Part 1) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic. If you have not registered for one of our webinars in the past, please subscribe to AOAAM (https://aoaam.org/subscribe), then login and register for the webinars. This webinar has been approved for a maximum 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    (Part 1) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. This lecture will discuss care of pregnant and postpartum people with Opioid Use Disorder and their families and discuss and debunk common myths and misperceptions. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic.

    If you have not registered for one of our webinars in the past, please subscribe to AOAAM, then login and register for the webinars.

    Goals & Objectives: 

    1. Review limitations and biases in presenting existing national prevalence data in perinatal opioid use
    2. Describe treatment considerations for women with OUD during pregnancy Explore the unique stigma and discrimination surrounding pregnancy and SUD treatment
    3. Identify opportunities for improved engagement, care, and collaboration in preparation for delivery. 
    4. Discuss the unique risks to substance-exposed families in the early postpartum period, including recurrence of substance use

    This webinar series has been approved for a maximum 6, AOA Category 1-A CME credits, and AOA designates this for a maximum of 6, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Davida Schiff, MD

    MassGeneral for Children

    Dr. Schiff is a general academic pediatrician and health services researcher focused on understanding how substance use in pregnant and parenting women impacts the health of children and families. She is the Medical Director of the HOPE Clinic (Harnessing support for Opioid and substance use disorder in Pregnancy and Early childhood) at Massachusetts General Hospital, a multidisciplinary program caring for women and families with substance use disorder from the time of conception through the first two years postpartum.

    Dr. Schiff completed her undergraduate training at Columbia University, medical training at the Boston University School of Medicine, pediatrics residency in the Boston Combined Residency Program at Boston Medical Center and Boston Children’s Hospital, general pediatrics research fellowship at Boston Medical Center, and master’s program in health services research from the Boston University School of Public Health. Her research is focused on improving care for families affected by substance use and her past scholarship has been published in the New England Journal of Medicine, JAMA, Pediatrics, Academic Pediatrics, Journal of Substance Abuse and Treatment, and Substance Abuse, among other journals. She is an Assistant Professor of pediatrics at Harvard Medical School.

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM Past President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and Bridge Clinic, as well as the Narcotic Addiction Treatment Program.
    Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions. Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder. She is the Immediate Past President of the American Osteopathic Academy of Addiction Medicine.